Skip to main content
. 2019 May 24;21(11):1389–1400. doi: 10.1093/neuonc/noz093

Fig. 6.

Fig. 6

LLS2 have antitumor activity in NF1−/− NF96.2 xenograft model. (A) Xenograft tumors. (B) Volume and (C) weight of the tumor xenografts were measured at 3 weeks after treatment. (D) Timeline of LLS2 treatment protocol; bioluminescent images for vehicle (8.7% alcohol/8.7% cremophor) or LLS2 treated mice were obtained at 12 weeks after initial i.v. injection of NF96.2 cells. **P < 0.01, ***P < 0.001; 2-tailed Student’s t-test, n = 6. Data shown are mean ± SD.